Ozempic reduces risk of 13 types of cancer
Patients taking semaglutide (the active ingredient in Wegovy and Ozempic) were 19% less likely to develop 13 obesity-related cancers, according to new data presented at ASCO 2024. The research, led by the Case Western Reserve University in Ohio and reported in The Guardian, also found… Read More